BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3479635)

  • 21. Immunohistochemical analysis of the distribution of lymphocyte subpopulations in Hodgkin's disease.
    Borowitz MJ; Croker BP; Metzgar RS
    Cancer Treat Rep; 1982 Apr; 66(4):667-74. PubMed ID: 6210433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts.
    Lin K; Nagy JA; Xu H; Shockley TR; Yarmush ML; Dvorak HF
    Cancer Res; 1994 Apr; 54(8):2269-77. PubMed ID: 8174137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
    Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
    Ravindranath NM; Nishimoto K; Chu K; Shuler C
    Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity of anti-Leu-M1 as a marker in Hodgkin's disease.
    Frierson HF; Innes DJ
    Arch Pathol Lab Med; 1985 Nov; 109(11):1024-8. PubMed ID: 3840354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies against SU-DHL-1 cells stain the neoplastic cells in true histiocytic lymphoma, malignant histiocytosis, and Hodgkin's disease.
    Hsu SM; Pescovitz MD; Hsu PL
    Blood; 1986 Jul; 68(1):213-9. PubMed ID: 2424524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease.
    Oudejans JJ; Kummer JA; Jiwa M; van der Valk P; Ossenkoppele GJ; Kluin PM; Kluin-Nelemans JC; Meijer CJ
    Am J Pathol; 1996 Jan; 148(1):233-40. PubMed ID: 8546210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percentage of proliferating cell nuclear antigen (PCNA)-positive Reed-Sternberg cells in nodular sclerosis Hodgkin's disease.
    Kordek R; Biernat W; Niewiadomska H; Kupnicka D; Woźniak L; Domagała W; Osborn M
    Patol Pol; 1993; 44(3):129-31. PubMed ID: 7902558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
    Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.
    Jezewska E; Björkholm M; Giscombe R; Holm G; Tullgren O
    Clin Exp Immunol; 1985 Jul; 61(1):96-102. PubMed ID: 4042422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.
    Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunohistology of Hodgkin's disease--Reed-Sternberg cells and their variants.
    Angel CA; Warford A; Campbell AC; Pringle JH; Lauder I
    J Pathol; 1987 Sep; 153(1):21-30. PubMed ID: 3499498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigen presentation by Hodgkin's disease cells.
    Fisher RI; Cossman J; Diehl V; Volkman DJ
    J Immunol; 1985 Nov; 135(5):3568-71. PubMed ID: 3876389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis by fluorescence microscopy and flow cytometry of monoclonal antibodies produced against cell surface antigens.
    Bolaños B; Bodón Q; Jiménez T; García-Mayol D; Lavergne JA; Díaz AM
    P R Health Sci J; 1988 Apr; 7(1):35-8. PubMed ID: 3375422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for an intracellular pool of a migration inhibitory factor-associated, activation antigen of human mononuclear phagocytes, Mo3e.
    Todd RF; Adams MD; Rogers CE; Tripp LR; Liu DY
    J Immunol; 1988 Feb; 140(4):1095-100. PubMed ID: 3278059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and ultrastructural study of Leu M1 antigen in Reed-Sternberg cells: comparison with granulocytes and interdigitating reticulum cells.
    Hsu SM; Huang LC; Hsu PL; Ge ZH; Ho YS; Cuttita F; Mulshine J
    J Natl Cancer Inst; 1986 Aug; 77(2):363-70. PubMed ID: 3090338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.